Gutaperka reported around three months of expression in mice after LNP delivery as part of its in vivo CAR-T work using circVec.
Public source
Publisher name
Public post
Three months of expression after LNP delivery sounds impressive. But does the therapy need three months? In vivo CAR-T aims to reprogram T cells directly inside the body…
Company
Gutaperka
Turning science into solutions
- Industry
- Business Consulting and Services
- Company size
- 1 employee
About Gutaperka
GUTAPERKA supports biotech and pharmaceutical leadership teams in transforming complex science into clear, actionable strategy. We work with executive teams, venture builders, and public–private R&D programs to bridge the gap between innovation, organization, and delivery. Combining hands-on experience in R&D, process development, and executive management, we help leaders focus, align, and execute. GUTAPERKA takes its name from gutta-percha, a natural material once prized for its flexibility and insulating strength. It was discovered in 1843 by a Singapore-based surgeon, William Montgomerie, who realized that the milky latex used by local craftsmen could be molded when warm and hardened when cool: a natural polymer centuries ahead of its time. It symbolizes what the company stands for: connecting, protecting, and structuring complex systems so ideas can flow and perform.
See moreLatest activity
Latest activity from Gutaperka
3 signals
Research & Knowledge
Gutaperka highlights a new study published by the University of Wisconsin–Madison suggesting that transfection efficiency may not be the optimal optimization target for cell therapies requiring sequential engineering steps.
Research & Knowledge
Gutaperka published a new study comparing six helper phospholipids in liposomal nanoparticles to determine their biological performance.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Circio Holding ASA
Circio Holding ASA presented new R&D results and updates from a strong first half of 2026, including circVec expression in the CNS, circVec design features for the heart, a therapeutic gene in vivo circVec-AAV expression advantage, T-cell-tropic LNPs for the in vivo CAR-T program, 20+ active R&D collaborations, and approximately NOK 620 million in new capital.
Research & Knowledge
Matica Biotechnology, Inc.
Matica Biotechnology, Inc. reported that a St. Jude team co-delivered lentiviral vectors with Cas9-containing virus-like particles to generate gene-edited CAR-T cells achieving greater than 70% editing across multiple targets while recovering roughly twice as many cells as electroporation in the head-to-head comparison.
Research & Knowledge
Phacilitate
Phacilitate reported that at day 17, about 70% of the circulating T cells in the mouse were CAR positive, resulting in very high transduction efficacy in vivo with a lentiviral vector.
Research & Knowledge
Helmholtz Munich
Helmholtz Munich researchers showed that STV-C8 enabled RNA expression after intravenous administration in mice and supported targeted gene editing in the muscle of a pig using components of the CRISPR/Cas9 system.
Research & Knowledge
NH Biotech Consulting